Evaluation of Tobacco Treatment Strategies for Inpatient Psychiatry

Status Active, not recruiting

Clinical Trial Summary

This study aims to evaluate, in a randomized controlled trial, tobacco treatments of varying intensities for smokers hospitalized on acute psychiatric inpatient units.

Clinical Trial Description

Using a three group additive design, this randomized clinical trial (N=1100) aims to evaluate tobacco cessation treatments of varying intensities initiated in the acute psychiatric inpatient setting. The three groups are:

1. Usual Care (N=150) consisting of brief cessation advice, a quit smoking guide, and nicotine replacement provided during hospitalization;

2. Brief Treatment (N=475) adds a stage-based manual, computer-delivered stage-tailored individualized feedback and brief cessation counseling sessions during hospitalization and repeated at months 3 and 6, and access to 12 weeks of nicotine replacement following hospitalization;

3. Extended Treatment (N=475) builds upon our current brief treatment and provides 12 additional weeks of nicotine replacement (24 weeks total) with individualized, counselor-delivered motivational and manualized cognitive behavioral cessation treatment.

This study seeks to determine: (i) whether the initial successes seen in an academic-based psychiatric hospital can be replicated in a larger and more diverse patient population; and (ii) if more extended and intensive treatment combining nicotine replacement therapy (NRT) with individualized, counselor-delivered motivational and manualized cessation-focused cognitive behavioral counseling (CBT) can outperform our current best practices. Ultimately, this research could lead to a model smoking cessation intervention for smokers with severe mental illness and, more generally, may provide a useful model for understanding the nature and complexity of intervening on comorbidities.

We hypothesize that the extended treatment will outperform the brief treatment, and that both treatment groups will be more effective than usual care in producing quit attempts and ultimately abstinence from cigarettes. Secondary specific aims will model the cost-effectiveness and budgetary impacts of the treatment conditions; examine moderators and mediators of treatment outcomes; and prospectively examine the relation between changes in smoking, mental health functioning, and use of other substances over time. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00968513
Study type	Interventional
Source	Stanford University
Contact
Status	Active, not recruiting
Phase	Phase 3
Start date	September 2009
Completion date	November 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01928719` - Reduced Nicotine Content Cigarettes in Smokers of Lower Socioeconomic Status	N/A
Completed	`NCT01995123` - Behavioral Activation for Smoking Cessation in PTSD	N/A
Not yet recruiting	`NCT03249428` - E-Cigarette Inner City RCT	N/A
Recruiting	`NCT02564289` - Cardiovascular Effects of Chronic Snus Use	N/A
Completed	`NCT01928758` - Reduced Nicotine Cigarettes in Smokers With Mood and Anxiety Disorders	N/A
Withdrawn	`NCT01847300` - cSBI-M for Young Military Personnel	N/A
Completed	`NCT01428310` - Study to Evaluate the Safety and Efficacy of Dietary Supplement Anatabloc in Reducing Daily Smokers' Urge to Smoke	Phase 1
Completed	`NCT01570595` - Positively Smoke Free on the Web (PSFW) for Smokers Living With HIV	Phase 1/Phase 2
Recruiting	`NCT00977249` - Varenicline for Long-term Nicotine Replacement Therapy (NRT) Users	Phase 2/Phase 3
Completed	`NCT00747643` - Varenicline Effects on Cue Reactivity and Smoking Reward/Reinforcement	N/A
Completed	`NCT01113424` - Bioequivalence Between Nicotine Replacement Products and Nicorette® Gum	N/A
Completed	`NCT00722124` - S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence	Phase 2/Phase 3
Completed	`NCT01238627` - Bioequivalence Between Two Oral Nicotine Sublingual Tablets, 2 mg and 4 mg	N/A
Completed	`NCT01228617` - Single-dose Pharmacokinetics of Oral Nicotine Replacement Products	N/A
Completed	`NCT00296647` - Smoking Cessation Intervention: Effectiveness in Primary Care	Phase 4
Completed	`NCT00394420` - Emergency Department Telephone Quitline	N/A
Recruiting	`NCT05487807` - Adapting and Evaluating a Tobacco Use Cessation Program for People Living With HIV in Uganda and Zambia	Phase 1
Completed	`NCT03553992` - An Extended Facebook Intervention for Young Sexual and Gender Minority Smokers	N/A
Withdrawn	`NCT05440721` - Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification	N/A
Completed	`NCT03694327` - Innovative Digital Therapeutic for Smoking Cessation	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.